OrbiMed Advisors
Latest statistics and disclosures from Orbimed Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are EWTX, LLY, BSX, Sinovac Biotech, EW, and represent 26.29% of Orbimed Advisors's stock portfolio.
- Added to shares of these 10 stocks: BMY (+$42M), ELV (+$35M), HELP (+$31M), PFE (+$29M), PRAX (+$28M), EW (+$26M), BRKR (+$26M), ESPR (+$22M), LXEO (+$21M), RAPT (+$19M).
- Started 23 new stock positions in LXEO, ACET, BRKR, KALV, KNSA, PALI, BCAX, ELV, BMY, PTCT. Cogent Biosciences, PHVS, VERA, HELP, MPLT, OCUL, ESPR, RVMD, TECX, PRAX, RLMD, PTGX, COGT.
- Reduced shares in these 10 stocks: TERN (-$219M), RNA (-$74M), EXAS (-$65M), AXSM (-$51M), SIBN (-$38M), SCPH (-$34M), ITGR (-$30M), IRON (-$28M), AKRO (-$25M), ARGX (-$22M).
- Sold out of its positions in ABT, Adicet Bio, AKRO, AMLX, AstraZeneca, Celcuity, Dih Hldg Us, ITGR, KZR, KRRO. LYEL, MIST, PASG, SRRK, SCPH, SIBN, TGTX, VSTM, XERS, MURA, Atai Life Sciences Nv, IMTX.
- Orbimed Advisors was a net seller of stock by $-434M.
- Orbimed Advisors has $4.9B in assets under management (AUM), dropping by 14.64%.
- Central Index Key (CIK): 0001055951
Tip: Access up to 7 years of quarterly data
Positions held by OrbiMed Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Orbimed Advisors
Orbimed Advisors holds 105 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Edgewise Therapeutics (EWTX) | 7.8 | $385M | 16M | 24.82 |
|
|
| Eli Lilly & Co. (LLY) | 6.6 | $324M | 301k | 1074.68 |
|
|
| Boston Scientific Corporation (BSX) | 4.7 | $231M | -7% | 2.4M | 95.35 |
|
| Sinovac Biotech SHS | 3.7 | $185M | 2.7M | 67.85 |
|
|
| Edwards Lifesciences (EW) | 3.5 | $170M | +18% | 2.0M | 85.25 |
|
| Upstream Bio (UPB) | 3.1 | $155M | 5.7M | 27.15 |
|
|
| Intuitive Surgical Com New (ISRG) | 3.0 | $149M | -8% | 263k | 566.36 |
|
| Sionna Therapeutics (SION) | 3.0 | $147M | -3% | 3.6M | 41.14 |
|
| Mbx Biosciences (MBX) | 2.5 | $124M | 3.9M | 31.54 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 2.5 | $123M | -15% | 146k | 840.95 |
|
| Enliven Therapeutics (ELVN) | 2.5 | $123M | 8.0M | 15.40 |
|
|
| Alnylam Pharmaceuticals (ALNY) | 2.3 | $115M | -4% | 289k | 397.65 |
|
| Stryker Corporation (SYK) | 2.3 | $114M | -9% | 325k | 351.47 |
|
| Silverback Therapeutics (SPRY) | 2.0 | $97M | 8.3M | 11.65 |
|
|
| Terns Pharmaceuticals (TERN) | 1.8 | $87M | -71% | 2.2M | 40.40 |
|
| Disc Medicine (IRON) | 1.7 | $85M | -24% | 1.1M | 79.41 |
|
| Caris Life Sciences (CAI) | 1.7 | $84M | +2% | 3.1M | 26.98 |
|
| Natera (NTRA) | 1.7 | $84M | -14% | 366k | 229.09 |
|
| Compass Therapeutics (CMPX) | 1.7 | $82M | 15M | 5.37 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.6 | $81M | 1.2M | 69.55 |
|
|
| Danaher Corporation (DHR) | 1.4 | $69M | +13% | 300k | 228.92 |
|
| Cg Oncology (CGON) | 1.3 | $63M | -12% | 1.5M | 41.52 |
|
| Apellis Pharmaceuticals (APLS) | 1.2 | $61M | -5% | 2.4M | 25.12 |
|
| Arrivent Biopharma (AVBP) | 1.2 | $61M | 3.0M | 20.12 |
|
|
| Cigna Corp (CI) | 1.1 | $56M | +25% | 205k | 275.23 |
|
| Rapt Therapeutics Com New (RAPT) | 1.1 | $56M | +51% | 1.6M | 33.87 |
|
| Corvus Pharmaceuticals (CRVS) | 1.1 | $55M | 7.2M | 7.70 |
|
|
| United Therapeutics Corporation (UTHR) | 1.0 | $51M | -8% | 105k | 487.25 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.0 | $50M | -3% | 368k | 134.85 |
|
| Roivant Sciences SHS (ROIV) | 1.0 | $48M | -19% | 2.2M | 21.70 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.9 | $47M | -16% | 999k | 46.55 |
|
| Axsome Therapeutics (AXSM) | 0.9 | $46M | -52% | 253k | 182.64 |
|
| Eyepoint Com New (EYPT) | 0.9 | $45M | +37% | 2.5M | 18.27 |
|
| Avidity Biosciences Ord (RNA) | 0.9 | $45M | -62% | 620k | 72.13 |
|
| Neurocrine Biosciences (NBIX) | 0.9 | $45M | -11% | 314k | 141.83 |
|
| Dyne Therapeutics (DYN) | 0.9 | $43M | -4% | 2.2M | 19.56 |
|
| Imagenebio Nonvoting | 0.9 | $43M | 6.2M | 6.90 |
|
|
| Bristol Myers Squibb (BMY) | 0.8 | $42M | NEW | 775k | 53.94 |
|
| Pfizer (PFE) | 0.8 | $41M | +230% | 1.7M | 24.90 |
|
| Trevi Therapeutics (TRVI) | 0.8 | $40M | -3% | 3.2M | 12.52 |
|
| Neuropace (NPCE) | 0.8 | $37M | -7% | 2.4M | 15.44 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.7 | $37M | -10% | 172k | 213.24 |
|
| EXACT Sciences Corporation (EXAS) | 0.7 | $36M | -64% | 352k | 101.56 |
|
| Mineralys Therapeutics (MLYS) | 0.7 | $36M | -33% | 980k | 36.29 |
|
| Anthem (ELV) | 0.7 | $35M | NEW | 99k | 350.55 |
|
| Forte Biosciences Com New (FBRX) | 0.7 | $33M | 1.2M | 27.27 |
|
|
| Prelude Therapeutics (PRLD) | 0.6 | $32M | 11M | 2.90 |
|
|
| Cybin Com New (HELP) | 0.6 | $31M | NEW | 3.8M | 8.18 |
|
| Oric Pharmaceuticals (ORIC) | 0.6 | $30M | 3.6M | 8.18 |
|
|
| Krystal Biotech (KRYS) | 0.6 | $30M | +16% | 120k | 246.54 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.6 | $28M | NEW | 95k | 294.74 |
|
| Janux Therapeutics (JANX) | 0.5 | $27M | +10% | 2.0M | 13.80 |
|
| Thermo Fisher Scientific (TMO) | 0.5 | $27M | 47k | 579.45 |
|
|
| Bruker Corporation (BRKR) | 0.5 | $26M | NEW | 556k | 47.11 |
|
| Rhythm Pharmaceuticals (RYTM) | 0.5 | $26M | +11% | 240k | 107.04 |
|
| Shattuck Labs (STTK) | 0.5 | $23M | 6.3M | 3.65 |
|
|
| Esperion Therapeutics (ESPR) | 0.4 | $22M | NEW | 6.0M | 3.70 |
|
| Avalo Therapeutics Com New (AVTX) | 0.4 | $22M | -12% | 1.2M | 18.16 |
|
| Lexeo Therapeutics (LXEO) | 0.4 | $21M | NEW | 2.1M | 9.93 |
|
| Adc Therapeutics Sa SHS (ADCT) | 0.4 | $21M | 5.8M | 3.53 |
|
|
| Urogen Pharma (URGN) | 0.4 | $21M | +27% | 876k | 23.42 |
|
| Xenon Pharmaceuticals (XENE) | 0.4 | $20M | +6% | 447k | 44.82 |
|
| Brightspring Health Svcs (BTSG) | 0.4 | $18M | +18% | 489k | 37.45 |
|
| Vera Therapeutics Cl A (VERA) | 0.4 | $18M | NEW | 354k | 50.64 |
|
| Uniqure Nv SHS (QURE) | 0.4 | $18M | +60% | 737k | 23.93 |
|
| Mind Medicine Mindmed Com New (MNMD) | 0.3 | $16M | +233% | 1.2M | 13.39 |
|
| Keros Therapeutics (KROS) | 0.3 | $16M | -21% | 804k | 20.36 |
|
| Carlsmed (CARL) | 0.3 | $16M | 1.3M | 12.35 |
|
|
| Cytomx Therapeutics (CTMX) | 0.3 | $15M | -58% | 3.5M | 4.26 |
|
| Vir Biotechnology (VIR) | 0.3 | $14M | 2.4M | 6.03 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 0.3 | $14M | +93% | 1.7M | 7.80 |
|
| Cogent Biosciences (COGT) | 0.3 | $13M | NEW | 371k | 35.52 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.3 | $13M | +36% | 1.6M | 8.14 |
|
| Tarsus Pharmaceuticals (TARS) | 0.3 | $13M | -21% | 154k | 81.88 |
|
| Relmada Therapeutics (RLMD) | 0.3 | $13M | NEW | 2.6M | 4.83 |
|
| Tectonic Therapeutic (TECX) | 0.2 | $12M | NEW | 575k | 20.86 |
|
| Alumis (ALMS) | 0.2 | $11M | -42% | 1.1M | 9.76 |
|
| Bioage Labs (BIOA) | 0.2 | $11M | 791k | 13.23 |
|
|
| Amicus Therapeutics (FOLD) | 0.2 | $10M | -55% | 730k | 14.24 |
|
| Aadi Bioscience (WHWK) | 0.2 | $10M | 4.2M | 2.42 |
|
|
| Adicet Bio Com New (ACET) | 0.2 | $8.7M | NEW | 1.0M | 8.42 |
|
| Repare Therapeutics Ord | 0.2 | $8.6M | 3.3M | 2.60 |
|
|
| Celcuity (CELC) | 0.2 | $8.5M | 86k | 99.74 |
|
|
| Jade Biosciences Com New (JBIO) | 0.2 | $8.2M | 531k | 15.43 |
|
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.2 | $7.7M | NEW | 187k | 41.25 |
|
| Q32 Bio (QTTB) | 0.2 | $7.5M | 2.3M | 3.32 |
|
|
| Pmv Pharmaceuticals (PMVP) | 0.1 | $6.2M | -16% | 5.0M | 1.25 |
|
| Kalvista Pharmaceuticals (KALV) | 0.1 | $6.2M | NEW | 382k | 16.15 |
|
| Pharvaris N V (PHVS) | 0.1 | $5.7M | NEW | 205k | 27.75 |
|
| Inspiremd (NSPR) | 0.1 | $5.6M | +46% | 3.1M | 1.78 |
|
| Insmed Com Par $.01 (INSM) | 0.1 | $4.4M | +88% | 25k | 174.04 |
|
| Palisade Bio (PALI) | 0.1 | $4.4M | NEW | 1.9M | 2.35 |
|
| Bicara Therapeutics (BCAX) | 0.1 | $3.5M | NEW | 209k | 16.83 |
|
| Cullinan Oncology (CGEM) | 0.1 | $2.8M | -85% | 270k | 10.35 |
|
| C4 Therapeutics Com Stk (CCCC) | 0.1 | $2.7M | -73% | 1.4M | 1.91 |
|
| Imagenebio (IMA) | 0.1 | $2.6M | 379k | 6.90 |
|
|
| Alto Neuroscience Com Shs (ANRO) | 0.0 | $2.2M | -50% | 125k | 17.80 |
|
| Revolution Medicines (RVMD) | 0.0 | $2.1M | NEW | 26k | 79.65 |
|
| Vistagen Therapeutics Ord Call Option (VTGN) | 0.0 | $2.1M | 3.1M | 0.66 |
|
|
| Ocular Therapeutix (OCUL) | 0.0 | $1.9M | NEW | 157k | 12.14 |
|
| Protagonist Therapeutics (PTGX) | 0.0 | $1.9M | NEW | 22k | 87.34 |
|
| Ptc Therapeutics I (PTCT) | 0.0 | $1.8M | NEW | 23k | 75.96 |
|
| Cogent Biosciences Note 1.625%11/1 (Principal) | 0.0 | $1.2M | NEW | 1.0M | 1.17 |
|
| Maplight Therapeutics (MPLT) | 0.0 | $952k | NEW | 56k | 17.00 |
|
| Traws Pharma Com New (TRAW) | 0.0 | $684k | 606k | 1.13 |
|
Past Filings by Orbimed Advisors
SEC 13F filings are viewable for Orbimed Advisors going back to 2010
- Orbimed Advisors 2025 Q4 filed Feb. 17, 2026
- Orbimed Advisors 2025 Q3 filed Nov. 14, 2025
- Orbimed Advisors 2025 Q2 filed Aug. 14, 2025
- Orbimed Advisors 2025 Q1 filed May 15, 2025
- Orbimed Advisors 2024 Q4 filed Feb. 14, 2025
- Orbimed Advisors 2024 Q3 filed Nov. 14, 2024
- Orbimed Advisors 2024 Q2 filed Aug. 14, 2024
- Orbimed Advisors 2024 Q1 filed May 15, 2024
- Orbimed Advisors 2023 Q4 filed Feb. 14, 2024
- Orbimed Advisors 2023 Q3 filed Nov. 14, 2023
- Orbimed Advisors 2023 Q2 filed Aug. 14, 2023
- Orbimed Advisors 2023 Q1 filed May 15, 2023
- Orbimed Advisors 2022 Q4 filed Feb. 14, 2023
- Orbimed Advisors 2022 Q3 filed Nov. 14, 2022
- Orbimed Advisors 2022 Q2 filed Aug. 15, 2022
- Orbimed Advisors 2022 Q1 filed May 16, 2022